Results 111 to 120 of about 6,459 (257)

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354

Frontiers in Pharmacology
Type 2 diabetes (T2D) and obesity are prevalent metabolic disorders affecting millions of individuals worldwide. A new effective therapeutic drug called tirzepatide for the treatment of obesity and T2D is a dual agonist of the GIP receptor and GLP-1 ...
Tayla A. Rees, Tayla A. Rees, Tayla A. Rees, Benjamin J. Buttle, Zoe Tasma, Zoe Tasma, Sung-Hyun Yang, Paul W. R. Harris, Paul W. R. Harris, Paul W. R. Harris, Christopher S. Walker, Christopher S. Walker   +11 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Tirzepatide - A Revolution in Obesity Treatment?

Introduction and aim of study: Obesity is a chronic disease associated with numerous health complications, and the number of patients is steadily increasing. Pharmacological methods for treating obesity are becoming increasingly popular.
Wojciechowska, Klara, Turek, Monika, Jaroń, Aleksandra, Chaberska, Iwona, Feruś, Aleksandra, Piątkowska, Karolina, Lipska, Julia, Jastrzębska, Katarzyna   +7 more
core   +1 more source

TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE

Tirzepatide is a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors that offers promising therapeutic potential beyond glycemic control.
Marcelina Broda, Izabela Szczap, Patrycja Jędrzejewska-Rzezak, Kamil Marzec, Katarzyna Urbańska, Adam Żuczek, Anna Hawryluk, Kinga Dyndał, Olga Żuczek, Aleksandra Mokrzycka   +9 more
core   +2 more sources

The Possible Link Between Tirzepatide and Pulmonary Embolism: A Case Report and a Narrative Review

Endocrines
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a prevalent condition with a significant annual incidence, particularly increasing with age.
Anna Arecco, Francesco Cocchiara, Davide Carlo Maggi   +2 more
doaj   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

Who Wins the Battle Against Obesity? A Network Meta‐Analysis Comparing Tirzepatide and Semaglutide

Journal of Diabetes
Introduction Pharmacological therapies are recommended for individuals with obesity. Semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1), and tirzepatide, a dual glucose‐dependent insulinotropic polypeptide and GLP‐1 receptor agonist (GIP/GLP‐
Julia C. Bernardi, Deivyd V. S. Cavalcante, Ramon Huntermann, Maria E. Molinari, Luana Z. Zanon, Jacinthe Khater, Victor A. Gomez, Caroline O. Fischer‐Bacca   +7 more
doaj   +1 more source

Prevalence of Obesity and Related Conditions and GLP‐1 Use in Medicare Fee‐for‐Service Beneficiaries

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study estimated the number and percentage of Medicare fee‐for‐service (FFS) beneficiaries who use GLP‐1 RAs, are currently eligible or could become eligible if ongoing‐trial indications receive approval and coverage. Materials and Methods This retrospective cohort study used Medicare enrolment and claims data, representing 100% of ...
Sonia Kim, Andrea Barthel, Marlene Smurzynski, Joanna MacEwan   +3 more
wiley   +1 more source

Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes

Obesity is a main trigger for development of type 2 diabetes. Tirzepatide is a dual receptor agonist of glucagon-like 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and is a potent agent for controlling glycemic control and reducing ...
Nasser Mikhail
core   +2 more sources

Cardiovascular Efficacy of GLP‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the cardiovascular efficacy and absolute benefit of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) by baseline estimated glomerular filtration rate (eGFR). Materials and Methods PubMed and EMBASE were searched to 29 April 2026 for randomized placebo‐controlled trials of GLP‐1RAs in adults with type 2 diabetes or ...
Masashi Hasebe, Chen‐Yang Su, Daisuke Yabe, Satoshi Yoshiji   +3 more
wiley   +1 more source